Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Rozenbaum Moshe H reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Moshe H Rozenbaum reported an equity compensation grant of 11,485 ordinary shares in the form of restricted stock units (RSUs). The award was granted on March 25, 2026 under the company’s 2025 Incentive Compensation Plan at a grant price of $0.0000 per share.
The 11,485 RSUs vest ratably in four equal quarterly installments starting three months from the grant date, meaning the director earns the shares over time rather than all at once. After this grant, Rozenbaum’s reported direct holdings total 11,485 ordinary shares.
Lifeward Ltd. director Moshe H Rozenbaum filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The structured data shows no reported transactions or derivative positions at this time.
Lifeward Ltd. reported that it has restored compliance with a key Nasdaq corporate governance rule. The company previously fell out of compliance with Nasdaq Listing Rule 5605(c)(2)(A) after director Hadar Levy resigned from the Board and its Audit Committee, leaving the committee below the required three members.
Nasdaq staff sent written notice on March 30, 2026, acknowledging the appointments of Moshe Rozenbaum, William Mark Sigsbee and Yehuda Reznick to the Audit Committee and confirming that Lifeward now meets the three-member requirement. Nasdaq stated the company is again in compliance with the rule and that the matter is closed.
Lifeward Ltd. reported that Chief Financial Officer Adar Almog received a grant of stock options on 39,934 ordinary shares of the company. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The grant vests over four years, with 25% of the underlying shares vesting on March 25, 2027, and the remaining shares vesting in equal monthly installments over the following 36 months, contingent on continued service. Following this grant, Almog holds options to acquire 39,934 shares, reflecting routine, compensation-related equity rather than an open-market share purchase.
Lifeward Ltd. President and CEO Grant William Mark received a grant of stock options covering 172,698 ordinary shares. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The award vests over four years, with 25% of the underlying shares vesting on March 25, 2027. The remaining 75% vests in equal monthly installments over the following 36 months, contingent on his continued service, with potential acceleration under the applicable plan and grant terms.
Reznick Yehuda reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Yehuda Reznick reported an equity compensation grant rather than a market trade. He received 7,657 ordinary shares in the form of restricted stock units granted on March 25, 2026 under the 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments starting three months after the grant date, and his direct holdings following the grant total 7,657 shares.
Lifeward Ltd. director Nadav Kidron received an equity award valued in shares rather than cash. On the grant date of March 25, 2026, he was granted 7,657 restricted stock units (RSUs) under the company’s 2025 Incentive Compensation Plan at no cash purchase price.
The RSUs convert into ordinary shares in four equal quarterly installments, beginning three months after the grant date. Following this award, Kidron’s reported direct holdings total 7,657 ordinary shares, reflecting the shares issuable upon vesting of this initial RSU grant.
Kidron Miriam reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Miriam Kidron received a grant of 7,657 ordinary shares through restricted stock units under the company’s 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments beginning three months after the March 25, 2026 grant date, aligning compensation with ongoing service.
Lifeward Ltd. director Reznick Yehuda has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The available data shows no reported purchases, sales, option exercises, gifts, or other transactions in this filing.
Lifeward Ltd. director Nadav Kidron filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director of the company and shows no reportable transactions or derivative positions, indicating there were no changes in his holdings requiring disclosure at this time.